Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
North-West Univ. MAO-A compound 2d: sourced facts only. name: "The 4-chloroisatin substituted series (2a-d) showed exceptional MAO-A inhibition (2d: 0.040 ± 0.002 µM), while the unsubstituted, 5-, 6-, and 7-chloroisatin analogues (1a-e, 3a-c, 4a-b, and 5a-e) demonstrated high potency and selectivity toward MAO-B, the most active being 5d (0.018 ± 0.003 µM; selectivity index = 15 389)." [PMID:42603777]; target: "The 4-chloroisatin substituted series (2a-d) showed exceptional MAO-A inhibition (2d: 0.040 ± 0.002 µM), while the unsubstituted, 5-, 6-, and 7-chloroisatin analogues (1a-e, 3a-c, 4a-b, and 5a-e) demonstrated high potency and selectivity toward MAO-B, the most active being 5d (0.018 ± 0.003 µM; selectivity index = 15 389)." [PMID:42603777]; developer: "Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, South Africa." [PMID:42603777]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on North-West Univ. MAO-A compound 2d.